Author: Ravi Shankar

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company, today announced that Henri Steenkamp will step down from his position as Chief Financial Officer, Chief Compliance Officer, Treasurer and Secretary, effective October 31, 2026, for health-related reasons.

Mr. Steenkamp will continue to support the Company in a consulting capacity following the transition, providing continuity and institutional knowledge as the Company implements its expanded leadership structure. Mr. Steenkamp will also remain a member of the Company’s Board of Directors and CFO of the Company’s SBIC subsidiaries, where he will continue to contribute his long-standing knowledge of the Company’s business, investment platform, governance practices and strategic priorities.

The Company also announced the following leadership appointments, each effective October 31st, 2026:

• Christine Ramdihal has been promoted to Chief Accounting Officer and Treasurer, and will serve as the Company’s principal financial officer
• Rochelle Kracoff has been promoted to Chief Compliance Officer and Secretary
• James Soltesz has been appointed as Investment Manager and Vice President of Capital Markets

Ms. Ramdihal has served as Controller of Saratoga Investment and brings significant accounting, financial-reporting and audit experience to her expanded role. Prior to joining Saratoga Investment almost ten years ago, she spent seven years in external audit roles at CBIZ and BDO, serving clients in both general assurance and financial-services practices.

Ms. Kracoff has served as Assistant Chief Compliance Officer and Treasury Manager at Saratoga Investment since 2021, following four years with the Company as Compliance Manager. In her expanded role, she will continue to oversee the Company’s compliance program and support the Company’s continued focus on regulatory adherence, governance and risk management. Before joining Saratoga Investment in 2017, Ms. Kracoff held legal and compliance roles at Visium Asset Management and earlier legal-operations positions.

Mr. Soltesz is an Investment Manager of Saratoga Investment Advisors, LLC, the Company’s investment adviser. He is responsible for underwriting, trading and portfolio management activities related to the firm’s third-party CLO security business. In his expanded role as Investment Manager and Vice President of Capital Markets, Mr. Soltesz will expand his role to support the Company’s overall balance sheet management.

These promotions reflect Saratoga Investment’s established succession planning and the depth of its leadership team. Christine Ramdihal, Rochelle Kracoff and Jim Soltesz each bring meaningful functional experience, institutional knowledge and a strong understanding of the Company’s operating standards to their expanded responsibilities. Collectively, their backgrounds across accounting, financial reporting, compliance, treasury, investment and balance sheet management and portfolio oversight provide a strong internal foundation for the transition.

Together with Mr. Steenkamp’s continued availability in a consulting capacity as well as his continued role on the Company’s Board of Directors and in the SBIC subsidiaries, these appointments are intended to support continuity across the Company’s finance, compliance, investment and governance functions. Saratoga Investment expects to maintain its disciplined approach to financial controls, regulatory compliance, risk management and stakeholder communications throughout the transition.

“On behalf of the Board and the entire Saratoga Investment team, I want to thank Henri for his significant contributions to the Company and his partnership over the years,” said Christian L. Oberbeck, Chairman and Chief Executive Officer of Saratoga Investment. “While we are sorry to see Henri step away from certain executive roles for health-related reasons, we fully support his decision to prioritize his health. We are grateful that he will remain engaged as a member of our Board, with our SBIC subsidiaries and be available in a consulting capacity ensuring a smooth transition. Christine, Rochelle and Jim are highly capable leaders with deep knowledge of our business and operating standards, and we are confident in their ability to provide continuity, disciplined execution and strong oversight as we advance Saratoga Investment’s strategic priorities.”

Mr. Steenkamp added, “It has been a privilege to serve Saratoga Investment, our Board, our shareholders and our dedicated team. I am proud of the Company’s progress and of the strong financial, compliance and investment capabilities we have built over the years, as well as the strength of the team that remains. While I am stepping away from my executive responsibilities to focus on my health, I remain fully committed to Saratoga Investment’s long-term success and look forward to continuing to support the Company as a director and in a consulting capacity during this transition.”

About Saratoga Investment

Saratoga Investment is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Saratoga Investment’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. Saratoga Investment has elected to be regulated as a business development company under the Investment Company Act of 1940 and is externally managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies. Saratoga Investment Corp. owns two active SBIC-licensed subsidiaries, having surrendered its first license after repaying all debentures for that fund following the end of its investment period and subsequent wind-down. Furthermore, it manages a $350 million collateralized loan obligation (“CLO”) fund that has recently repriced and reset its reinvestment period and co-manages a joint venture (“JV”) fund that owns a $400 million collateralized loan obligation (“JV CLO”) fund, and has equity and junior security investments in both CLO’s. The Company’s diverse funding sources, combined with a permanent capital base, enable Saratoga Investment to provide a broad range of financing solutions.

Forward Looking Statements

This press release contains historical information and forward-looking statements with respect to the business and investments of the Company, including, but not limited to, the statements about future events or our future performance or financial condition. Forward-looking statements can be identified by the use of forward looking words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or negative versions of those words, other comparable words or other statements that do not relate to historical or factual matters. The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, but not limited to: changes in the markets in which we invest; changes in the financial, capital, and lending markets; an economic downturn or a recession and its impact on the ability of our portfolio companies to operate and the investment opportunities available to us; the impact of interest rate volatility on our business and our portfolio companies; the uncertainty associated with the imposition of tariffs and trade barriers and changes in trade policy and its impact on our portfolio companies and the global economy; the impact of supply chain constraints and labor shortages on our portfolio companies; and the elevated levels of inflation and its impact on our portfolio companies and the industries in which we invests, as well as those described from time to time in our filings with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which it is made. The Company undertakes no duty to update any forward-looking statements made herein or on the webcast/conference call, whether as a result of new information, future developments or otherwise, except as required by law. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2026 and subsequent filings, including the “Risk Factors” sections therein, with the Securities and Exchange Commission for a more complete discussion of the risks and other factors that could affect any forward-looking statements. 

Contacts:

Saratoga Investment Corporation
535 Madison Avenue, 4th Floor
New York, NY 10022

Henri Steenkamp
Chief Financial Officer
Saratoga Investment Corp.
212-906-7800

Lena Cati
The Equity Group Inc.
212-836-9611 / lena.cati@theequitygroup.com

Val Ferraro
The Equity Group Inc.
212-836-9633 / val.ferraro@theequitygroup.com

LAS VEGAS, Sept. 18, 2026 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading distributor of international foodservice solutions to Asian restaurants and other businesses across the United States and Canada, today announced that it has terminated the Sales Agreement among the Company, D.A. Davidson & Co. and Roth Capital Partners, LLC, dated September 25, 2025 (the “Sales Agreement”) and the At-The-Market (“ATM”) equity offering program it established on September 25, 2025, under which the Company could sell shares of its common stock for aggregate gross proceeds of up to $100 million. The termination is effective as of September 24, 2026.

About HF Foods Group Inc.

HF Foods Group Inc. is a leading marketer and distributor of fresh produce, frozen and dry food, and non-food products to primarily Asian restaurants and other foodservice customers throughout the United States and Canada. HF Foods aims to supply the increasing demand for Asian American restaurant cuisine, leveraging its nationwide network of distribution centers and its strong relations with growers and suppliers of fresh, high-quality specialty restaurant food products and supplies in the US and Asia. Headquartered in Las Vegas, Nevada, HF Foods trades on Nasdaq under the symbol “HFFG”. For more information, please visit www.hffoodsgroup.com.

Safe Harbor Disclosure

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, and typically can be identified by the use of words such as “expect,” “estimate,” “target,” “anticipate,” “forecast,” “plan,” “outlook,” “believe” and similar terms. Such forward-looking statements include, but are not limited to, statements regarding the Company’s financial position, business strategy and the anticipated effects of the termination of the Sales Agreement and the ATM equity offering program.

Although the Company believes that the expectations are reasonable, it can give no assurance that these expectations will prove to be correct, and actual results may vary materially. Factors that could cause actual results to differ materially from those contemplated above include, among others, risks and uncertainties related to the capital markets generally.

HF Foods undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Additional information about factors that could cause HF Foods’ actual results to differ materially from those contemplated in the forward-looking statements included in this news release should be considered in connection with information regarding risks and uncertainties that may affect HF Foods’ future results included in HF Foods’ filings with the Securities and Exchange Commission (the “SEC”) at www.sec.gov. In addition, HF Foods makes available free of charge at https://investors.hffoodsgroup.com/financials/sec-filings, copies of materials it files with, or furnishes to, the SEC.

Contact:

ICR
Anna Kate Heller
hffoodsgroup@icrinc.com

FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective September 17, 2026, it granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.32 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO^® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on September 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 63,009 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

 – Expands complex injectables portfolio with important long-acting oncology treatment
 – Immediate commercial launch supported by in-house production

BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE^® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.

“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,” said Srinivas Kone, Ph.D., Senior Vice President and Chief Scientific Officer – Affordable Medicines. “Lanreotide is a significant addition to our expanding complex injectables portfolio and reflects the strength of our integrated development and manufacturing capabilities. With dedicated, large-scale in-house manufacturing capacity, we are well positioned to reliably supply the market, broaden access to this important medicine and create meaningful long-term value for patients, providers, and shareholders.”

U.S. annual sales for SOMATULINE^® Depot for the 12 months ended July 2026 were $983 million, per IQVIA^®.

Lanreotide Injection is indicated for: the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. It helps control hormone levels in acromegaly, improves progression-free survival in eligible GEP-NET patients, and reduces the need for rescue therapy in patients with carcinoid syndrome.

For full prescribing information, see package insert here.

Note: SOMATULINE^® Depot is a registered trademark of Ipsen Pharma S.A.S.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com

Singapore, Sept. 18, 2026 (GLOBE NEWSWIRE) — Webuy Global Ltd. (Nasdaq: WBUY) (“Webuy” or the “Company”), a technology-driven platform transforming travel services and social commerce across Southeast Asia, today announced that on September 14, 2026, it received a letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s Class A ordinary shares, par value US$0.0000462 per share (“Class A Ordinary Shares”), was below US$1.00 per share for 30 consecutive business days, from July 31, 2026, to September 11, 2026, and that the Company therefore does not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”).

This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Notification Letter has no immediate effect on the listing of the Company’s Class A Ordinary Shares, which will continue to trade uninterrupted on Nasdaq under the ticker “WBUY”.

Under Nasdaq Listing Rule 5810(c)(3)(A), Webuy has 180 calendar days, or until March 15, 2027, to regain compliance. If at any time during this period the closing bid price of the Class A Ordinary Shares is at least US$1.00 per share for a minimum of ten (10) consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.

If the Company does not regain compliance within the initial 180-day period, Webuy may be eligible for an additional 180 calendar days to regain compliance, provided that it otherwise meets the continued listing requirements for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market under Nasdaq Listing Rule 5505, except for the Minimum Bid Price Rule, and provides a written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If Webuy chooses to implement a reverse stock split, it must complete the split no later than ten (10) business days prior to March 15, 2027 in order to regain compliance during the initial compliance period. If it appears to Nasdaq that Webuy will not be able to cure the deficiency, or if Webuy is otherwise not eligible, Nasdaq will provide notice that the Class A Ordinary Shares will be subject to delisting, at which time Webuy may appeal the delisting determination to a Nasdaq Hearings Panel.

The Company is actively monitoring the situation and evaluating all reasonable measures available to regain compliance with the Minimum Bid Price Rule within the applicable compliance period. However, there can be no assurance that Webuy will be able to regain compliance with the Minimum Bid Price Rule or maintain compliance with Nasdaq’s other continued listing requirements.
  
About WEBUY GLOBAL LTD (Nasdaq: WBUY)

Webuy is a technology-driven platform transforming travel services and social commerce across Southeast Asia. The Company provides curated leisure travel experiences, cross-border tour services, premium travel offerings, customized travel solutions, and region-wide travel services for customers in Indonesia, Singapore, and international markets. Webuy is focused on building an integrated travel ecosystem powered by AI, service excellence, and strong regional partnerships. For more information, visit www.webuy.global.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results, and encourages investors to read the risk factors contained in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025 and other reports it files with the U.S. Securities and Exchange Commission (the “Commission”) before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequently occurring events or circumstances, or changes in its expectations, except as may be required by law.

CONTACT: WEBUY GLOBAL LTD
Email: ir@webuy.global

HERNDON, Va., Sept. 18, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) today announced the successful closing of its $612.5 million Navient Private Education Loan Trust (NAVSL) 2026-A transaction, the company’s fourth student loan securitization of the year. NAVSL 2026-A represents Navient’s first securitization designed to support investment by investors subject to the European Union’s securitization regulation and the United Kingdom’s securitization regulatory framework.

“Expanding access to our securitizations for investors operating under EU and UK regulatory frameworks reflects our ongoing commitment to the capital markets,” said Steve Hauber, chief financial officer of Navient. “We are pleased to structure this transaction with risk retention features designed to support these investors’ compliance needs while demonstrating our confidence in the quality of the underlying assets.”

Navient has agreed to retain a portion of the notes and certificates on terms designed to align with the risk retention requirements of the EU securitization regulation and the UK securitization regulatory framework and support the compliance needs of investors subject to the EU or UK requirements. Investors interested in the transaction should conduct their own assessment of the transaction and applicable regulatory requirements. Navient makes no representation or guarantee regarding the suitability of the notes or certificates for the satisfaction of any investor’s regulatory obligations.

Pricing and Yield:  

Class	Size (MM)	WAL	S&P/DBRS	Interest Rate
A	$448.0	2.96	AAA / AAA	SOFR30A	+105
B	$82.8	3.00	NR / AA	SOFR30A	+145
C	$43.4	3.64	NR / A	SOFR30A	+180
D	$10.0	3.68	NR / BBB	SOFR30A	+235
E	$28.3	3.89	NR / BB	SOFR30A	+450

Sole Book Runner: J.P. Morgan

About Navient
Navient (Nasdaq: NAVI) creates long-term value for customers and investors with responsible lending, flexible refinancing, trusted servicing oversight, and decades of education finance and portfolio management expertise. Through our Earnest business, we help customers confidently achieve financial success through digital financial services. Our employees thrive in a culture of belonging, where they are supported and proud to deliver meaningful outcomes. Learn more on Navient.com.

Contacts
Media: Cate Fitzgerald, 703-831-6347, catherine.fitzgerald@navient.com
Investors:	Micah Andrews, 571-415-5413, micah.andrews@navient.com
	Roger Yankoupe, 571-592-8569, roger.yankoupe@navient.com

September 18^th, 2026

DIAC : ‘’ Financial Report as at June 30^th 2026’’

The financial Report as at June 30^th 2026 is now available on the Mobilize Financial Services website www.mobilize-fs.com.

Attachment

• DIAC RFS H1 2026

• For the third time, TIME has named Grupo Bimbo among the world’s 1,000 best companies based on employee satisfaction, financial growth, and ESG performance.

MEXICO CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) — Grupo Bimbo, the leader and largest baking Company in the world, has been recognized for the third time in the World’s Best Companies 2026 ranking, compiled by TIME in partnership with Statista.

In this year’s edition, Grupo Bimbo ranked among the highest-positioned Mexican companies included in the publication. The Company was also ranked 560 globally among the 1,000 companies selected and was one of only 46 food and beverage companies featured in the 2026 ranking.

Grupo Bimbo closed 2025 with record levels of Net Sales and Adjusted EBITDA, which increased by 4.6% and 7.2%, respectively. These results reflect the strength and resilience of its business model and build on a decade of sustained growth. This performance was further complemented by significant progress across its sustainability agenda.

These achievements underscore Grupo Bimbo’s commitment to creating value for people, communities, and the planet. Guided by its purpose of Nourishing a Better World, the Company advances its sustainability strategy through three pillars: Baked For You, Baked For Life, and Baked For Nature.

Under its pillar, Baked For You, 48% of Grupo Bimbo’s sales came from products classified as Positively Nourishing, meaning they meet or exceed optimal nutrition standards under the Health Star Rating system. In addition, 100% of its everyday consumption portfolio is free from artificial colors, and 99% is free from artificial flavors.

Under its pillar, Baked For Life, Grupo Bimbo implemented 270 Good Neighbor projects, a program designed to strengthen relationships with communities near its operations through initiatives focused on education, wellbeing, the environment, and physical activity. The Company also continued to advance its diversity and inclusion efforts, reaching 30% women in leadership positions.

Under its pillar, Baked For Nature, 100% of the electricity consumed by the Company in 2025 came from renewable sources, including both Company-owned assets and off-site renewable energy projects. In addition, Grupo Bimbo supported more than 500,000 hectares cultivated using regenerative agricultural practices and achieved 99% recyclability compliance across its packaging portfolio.

About the World’s Best Companies 2026 Ranking

The ranking is a global analysis developed by TIME and Statista to identify the world’s top-performing companies. The assessment is based on three equally weighted dimensions:

• Employee Satisfaction: Surveys conducted in more than 50 countries with approximately 200,000 participants. The evaluation includes direct and indirect recommendations, as well as verified employee assessments of company image, workplace environment, working conditions, compensation, and equity.
• Revenue Growth: Companies were required to generate at least US$100 million in revenue in 2025 and demonstrate positive growth between 2022 and 2025.
• Sustainability (ESG): Assessed using standardized key performance indicators from Statista’s ESG Database, supplemented by company-specific research.

This recognition reflects the dedication of Grupo Bimbo’s more than 152,000 associates worldwide and the impact of its Philosophy to build a sustainable, highly productive, and deeply humane company. Through long-term, sustainable growth, Grupo Bimbo continues to create value for people, communities, and the planet.

About Grupo Bimbo

Grupo Bimbo is the leader and largest baking Company in the world and a relevant participant in snacks. It has a presence in 99 countries worldwide, operating directly in 39 and serving another 60 through strategic partnerships. Its operations span the Americas, Europe, Asia, and Africa, with 250 bakeries and snackeries, and more than 1,600 sales centers. With annual sales of over US$23 billion, the Company offers a diversified product portfolio, its main categories include sliced and artisan bread, buns & rolls, pastries, cakes, cookies, toasts, English muffins, bagels, tortillas & flatbreads, and salty snacks, among others. Grupo Bimbo operates one of the largest direct-store-delivery networks in the world, with more than 55,000 routes and over 152,000 associates. Its shares are listed on the Mexican Stock Exchange (BMV) under the ticker symbol BIMBO, and trade in the U.S. over-the-counter market through a Level 1 ADR under the ticker symbol BMBOY.

Grupo Bimbo Social Media: Sitio web | Facebook | X | LinkedIn | TikTok

Media Contacts:
Nina Negrin
Buchanan Public Relations
bbu@buchananpr.com

Roundtable is not acquiring PAAI, Private Stock Sale is a Condition of Close; Partnership Yields creates a $100 Million ad ecosystem with 40% margin, for RTB Enterprise Partners.

SEATTLE, Sept. 18, 2026 (GLOBE NEWSWIRE) — Roundtable (Nasdaq: RTB) today issued clarifying points regarding the Company’s 10-year, $1 billion agreement with The Arena Group, now Paradium.AI, to migrate, operate and monetize its premium media portfolio on Roundtable’s AI/DeFi-powered MediaOS, bringing global scale to its advanced platform.

The transaction is designed to migrate Paradium.AI’s brands, traffic and associated revenue to RTB’s full-stack, enterprise media platform, while creating immediate advertising scale for RTB’s enterprise customers. It is not an acquisition of Paradium.AI or a tender offer.

Summary of Clarifying Points

• RTB is not buying Paradium.AI. The companies entered into a 10-year Strategic Platform Agreement only
• There is no tender offer or open-market purchase. RTB is not buying shares from the public or company, but a minority interest, direct from the largest shareholder.
• RTB’s investment will remain below control. The shares represent a minority interest, and there are no plans, and does not wish to consolidate or acquire majority control.
• Closing is conditional and expected Q4 2026. Completion of the minority share purchase, including required capital raise, is a closing condition.
• The platform agreement includes $11.5 million of RTB stock consideration. In exchange for, technology license transfer and other considerations.
• Agreement does not add incremental expenses beyond RTB’s operating model. The functions RTB will provide Paradium.AI are the same required for other enterprise customers. The agreement simply accelerates required platform operations and staffing, with no added costs.
• RTB expects payback within two years from Platform margin. RTB expects the premium paid for the shares purchased to be capitalized and amortized over the 10-year agreement, with ROI payback within two years.
• The agreement is expected to create immediate marketplace scale. Based on forecasts, due diligence, public filings and assumptions, RTB believes the agreement could bring RTB’s marketplace to $100 million in annual gross revenue, 100 million monthly users and generate $1 billion over 10 years, subject to closing, market conditions and no material adverse change.

Additional terms, conditions and risk factors will be described in RTB’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on September 18, 2026.

About Roundtable (RTB Digital, Inc.)

Roundtable (NASDAQ: RTB) is the world’s only AI/DeFi-powered Enterprise Media Operating System, integrating distribution, publishing, monetization, community, syndication and DeFi payment operations, powering professional and major media brands. The Web3 platform was developed over years by digital pioneers and co-founders, Eyal Hertzog, and James Heckman.

For more information, visit rtb.io.

Cautionary Note Regarding Forward-Looking Statements

This press release includes information that constitutes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on the Company’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements that are characterized by future or conditional words such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate,” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such forward-looking statements include statements regarding the accretive transactions undertaken in 2026 and future operations and revenues of the company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results to differ materially from those expressed in or contemplated by the forward-looking statements, such as the company being able to maintain its listing on Nasdaq for the common stock, having sufficient capital for its acquisitions, operations and business expansion, and developing its business and capturing users for its services. Annualized and longer period revenue and business estimates are subject to the effect of macroeconomic events, to industry changes, to competitive forces, to client development and retention, to capital availability, and to many other operational factors; therefore, any financial forecasts offered by the Company must take into account the fact that the underlying assumptions may significantly change over time and projected results may substantively increase or decrease. Other risk factors affecting the Company are discussed in detail in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable laws.

Investor Relations Contact: ir@roundtable.io
Public Relations Contact: press@roundtable.io